Shares in Intersect ENT (NSDQ:XENT) have fallen slightly today despite the medical device maker releasing fourth quarter and full year 2018 earnings that met consensus expectations from analysts on Wall Street.
The Menlo Park, Calif.-based company posted losses of $5 million, or 16¢ per share, on sales of approximately $32.8 million for the three months ended December 31, seeing losses grow 59.6% while sales grew 11% compared with the same period during the previous year.
Intersect ENT’s loss-per-share numbers were just in line with the 16¢ consensus on Wall Street, where analysts expected to see sales of $32.5 million, which the company topped.
For the full year, Intersect ENT posted losses of $22.9 million, or 76¢ per share, on sales of $108.5 million, seeing losses grow 40.1% while sales grew 12.6% compared with the previous fiscal years.
The company was just ahead of the 75¢ loss-per-share expectations on Wall Street, where analysts expected to see sales of $108 million, which the company also topped.
Intersect ENT released guidance for the 2019 year, expecting to post sales of between $123 million and $127 million, with first quarter sales of between $26 million and $26.5 million, according to a press release.
Shares in Intersect ENT have fallen 2.6% today, at $33.65 as of 12:57 p.m. EST.
Last December, Intersect ENT said that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.